Journal Logo

OT Broadcasts from the iPad Archives

Oncology's top experts share their perspectives, opinions, and concerns about the field's most pressing issues covered in recent OT articles-originally featured in our iPad editions.



Subscribe to this podcast using
Creator: Peter Goodwin
Duration: 39:47

What’s in the OncTimesTalk, May 2021 Edition?

New clinical findings on:
Nivolumab in gastro-esophageal cancer, CDK4/6 inhibition for breast cancer, COVID-19 vaccination limitations, sitagliptin/graft-versus-host disease, breast cancer individualization, neo-adjuvant chemotherapy for rectal cancer.
Featuring:
Ronan Kelly (Austin TX), Erica Mayer (Boston MA), Sibylle Loibl (Frankfurt, Germany), Shabir Madhi (Johannesburg South Africa) and Thierry Conroy (Nancy, France).

Interviews in this edition:

Ronan J Kelly MD MBA, Baylor University Medical Center, Dallas
Adjuvant Nivolumab “Practice Changing” in Resected Gastroesophageal Cancer
Ronan Kelly tells OncTimesTalk about a big reduction in the risk of death, and doubling of median disease-free survival, from using nivolumab as adjuvant therapy for patients with esophageal, and gastro-esophageal junction, cancers after
chemoradiotherapy plus surgery in the placebo-controlled phase-three CheckMate 577 study.
https://www.nejm.org/doi/full/10.1056/NEJMoa2032125

Erica L. Mayer MD, Dana-Farber Cancer Institute, Boston, MA
Palbociclib Added No Benefit to Breast Cancer Adjuvant Endocrine Therapy
Erica Mayer discusses the PALLAS study findings with OncTimesTalk that adding the CDK 4/6 inhibitor palbociclib to endocrine therapy failed to improve invasive disease-free survival among patients with early breast cancer despite its proven efficacy in metastatic disease.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30642-2/fulltext

Breast Cancer: A Guide to Therapy Individualization 
Sibylle Loibl, Professor of Obstretrics and Gynaecology, University of Frankfurt, CEO and Chair, German Breast Group.
Sibylle Loibl discusses her expert panel’s findings with OncTimesTalk about optimizing the many powerful methods for managing breast cancer to individualize treatment. “Future research in breast cancer will focus not only on new drugs, but even more on the individualization of therapy for every single tumor in every single patient,” she wrote in “The Lancet”.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32381-3/fulltext

Sherif S. Farag MD PHD, Director of the Stem Cell Transplant and Cellular Therapy, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, in Indianapolis
Sitagliptin Reduced Graft Versus Host Disease in Stem Cell Transplantation
A non-randomized 36-patient phase-two clinical study found a big reduction in acute graft-versus-host disease after adding the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (a long established antiglycemic agent) to immunosuppression for allogeneic stem-cell transplantation.  Sherif Farag discusses the study findings with OncTimesTalk.
http://www.nejm.org/doi/full/10.1056/NEJMoa2027372

Shabir A. Madhi PhD, Professor of Vaccinology and Director of the Vaccines & Infectious Diseases Analytics Research Unit at the University of Witwatersrand in Johannesburg, Co-Director of African Leadership in Vaccinology Expertise.
SARS-CoV-2 Vaccine Was Ineffective Against B.1.351 (“South African”) Variant
A “first-generation” vaccine for COVID-19 failed to prevent mild or moderate disease caused by the B.1.351 coronavirus variant in South Africa in a randomized, double-blind, controlled trial of the ChAdOx1 nCoV-19 vaccine among relatively young adults. Shabir Madhi tells OncTimesTalk, however, that vaccination with such first-generation vaccines should still protect against severe disease and death from the new variant because T-cell responses had been preserved in the South African variant.
https://www.nejm.org/doi/full/10.1056/NEJMoa2102214

Thierry Conroy MD, Professor, Department of Medical Oncology, Institut de Cancérologie de Lorraine, 54519 Vandoeuvre-lès-Nancy, France
Neoadjuvant Chemotherapy Before Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer
A multi-center, randomized, open-label, phase-three trial has shown that outcomes for patients with rectal cancer can be improved still further by using neoadjuvant chemotherapy before the current standard of care (chemo-radiotherapy and surgery).  Professor Thierry Conroy, from the Cancer Institute in Nancy, gives OncTimesTalk the details on why they decided to try an additional treatment and the benefit it brought.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00079-6/fulltext

Creator: Sarah LaCorte
Duration: 10:48
Liam Holt, PhD, speaks in analogies when describing his work focusing on compression of cancer cells and how it affects their behavior and evolution at his lab at the Institute for Systems Genetics at NYU Grossman School of Medicine. The assistant professor in the Department Of Biochemistry and Molecular Pharmacology aims to characterize how compression of cells causes genome instability specifically in pancreatic cancer.
Creator: Sarah LaCorte
Duration: 12:46
Oncology Times sits down with Brian J. Bolwell, MD, the Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine. In his recurring Oncology Times column Straight Talk: Today's Cancer Centers, Dr. Bolwell dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell discusses the art of forgiveness; including how to let it go when there is conflict and breach of trust.
Creator: Lola Butcher
Duration: 3:15

David E. Weissman, MD, founded the Palliative Care Center at the Medical College of Wisconsin, serves as Director of the Medical School Palliative Care Education Project, and is also Co-Director of the Center to Advance Palliative Care’s initiative to help oncs meet revised standards of care (Improving Palliative Care—Outpatients [OPAL-OP]).

Listen to what he told OT are the trends in palliative care he sees in practice.

Creator: Lola Butcher
Duration: 9:37
Lowell E. Schnipper, MD, Chair of ASCO’s Cost of Care Taskforce and Chief of Hematology/Oncology at Beth Israel Deaconess Medical Center in Boston, explains which procedures made ASCO’s “Top Five” list of unnecessary oncology services—part of the American Board of Internal Medicine Foundation’s “Choosing Wisely” campaign.

Hear his discussion with OT Contributing Writer and “Practice Matters” blogger Lola Butcher.
Creator: Sarah DiGiulio
Duration: 14:25
Clifford A. Hudis, MD, Chief of the Breast Cancer Medicine Service of Memorial Sloan-Kettering Cancer Center and ASCO’s 2012-2013 President-Elect, explains why face-to-face networking and in-person meetings are important to oncology research, despite faster ways of information sharing.

Hear what he told OT Assistant Editor Sarah DiGiulio.
Creator: Lola Butcher
Duration: 7:59
Thomas L. Whittaker, MD, Immediate Past President of the Association of Community Cancer Centers, explains the implications of survey results that show most oncologists expect to be practicing in an oncology medical home or accountable care org within the next five years.

Hear his discussion with OT Contributing Writer and “Practice Matters” blogger Lola Butcher.
Creator: Sarah DiGiulio
Duration: 3:07
William Breitbart, MD, Acting Chair of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan-Kettering Cancer Center, explains how a cancer experience can change an individual’s sense of meaning and identity—and the psychotherapy intervention programs he developed.

Hear his discussion with OT Assistant Editor Sarah DiGiulio.
Creator: Lola Butcher
Duration: 9:18

Steven Schroeder, MD, Chairman of the newly formed National Commission on Physician Payment Reform, discusses the commission’s upcoming report on how physicians are paid and what pay incentives mean to patient care—and how oncologists can contribute their thoughts.

Hear his chat with OT Contributing Writer and “Practice Matters” blogger Lola Butcher.

Creator: Lola Butcher
Duration: 23:03
Thomas J. Smith, MD, Professor of Oncology and Director of Palliative Care at Johns Hopkins Medical Institutions, explains the benefits of making palliative care part of standard oncology care for patients—and the research behind it. Hear Smith’s discussion with OT Contributing Writer and “Practice Matters” blogger Lola Butcher.
Creator: Lola Butcher
Duration: 2:48
Steven Tucker, MD, a prostate cancer specialist, discusses “competitive mortality”—how understanding the other conditions in addition to cancer, like chronic disease, old age, and diabetes, that influence a patient’s risk of death improves care overall. Hear Tucker speaking with OT Contributing Writer and “Practice Matters” blogger Lola Butcher. And, read more about the new mortality-index website, ePrognosis, Tucker uses to compare geriatric prognosis indices in the full article.
Creator: Lola Butcher (OT columnist)
Duration: 2:31
Matt Brow, U.S. Oncology’s top public policy official, breaks down the details of the Medicare Shared Savings Program—the federal government’s final rule on making the accountable care organization model part of Medicare. Brow is the Vice President of Communications in Government and Relations & Public Policy for McKesson Specialty Care Solutions, the parent company of U.S. Oncology.
Creator: Lola Butcher
Duration: 8:52
Reginald Williams II, an Avalere Health Director, discusses his organization’s analysis of how the oncology landscape may be the next topic of scrutiny for the Centers for Medicare & Medicaid Services. Four topics may be ripe for national coverage decisions: lung and prostate cancer screenings, localized prostate cancer treatments, therapies to manage non-small-cell lung cancer, and pharmacogenomic testing for breast and colon cancers. Hear Williams’ discussion with OT Contributing Writer and “Practice Matters” blogger, Lola Butcher.
Show: